Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

TAM Receptor Inhibition-Implications for Cancer and the Immune System

Research output: Contribution to journalReviewResearchpeer-review

DOI

  1. Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC-Real World Efficacy

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Meningioma-Brain Crosstalk: A Scoping Review

    Research output: Contribution to journalReviewResearchpeer-review

  3. Pathologic Characteristics of Pregnancy-Related Meningiomas

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Long-Term Follow-Up and Predictors of Functional Outcome after Surgery for Spinal Meningiomas: A Population-Based Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. The capacity of CD4+ Vγ9Vδ2 T cells to kill cancer cells correlates with co-expression of CD56

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Vγ9Vδ2 T Cells Concurrently Kill Cancer Cells and Cross-Present Tumor Antigens

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Adrenergic Signaling in Immunotherapy of Cancer: Friend or Foe?

    Research output: Contribution to journalReviewResearchpeer-review

  4. Expansion With IL-15 Increases Cytotoxicity of Vγ9Vδ2 T Cells and Is Associated With Higher Levels of Cytotoxic Molecules and T-bet

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Tyro3, Axl and MerTK (TAM) receptors are receptor tyrosine kinases which play important roles in efferocytosis and in the balancing of immune responses and inflammation. TAM receptor activation is induced upon binding of the ligands protein S (Pros1) or growth arrest-specific protein 6 (Gas6) which act as bridging molecules for binding of phosphatidyl serine (PtdSer) exposed on apoptotic cell membranes. Upon clearance of apoptotic cell material, TAM receptor activation on innate cells suppresses proinflammatory functions, thereby ensuring the immunologically silent removal of apoptotic material in the absence of deleterious immune responses. However, in T cells, MerTK signaling is costimulatory and promotes activation and functional output of the cell. MerTK and Axl are also aberrantly expressed in a range of both hematological and solid tumor malignancies, including breast, lung, melanoma and acute myeloid leukemia, where they have a role in oncogenic signaling. Consequently, TAM receptors are being investigated as therapeutic targets using small molecule inhibitors and have already demonstrated efficacy in mouse tumor models. Thus, inhibition of TAM signaling in cancer cells could have therapeutic value but given the opposing roles of TAM signaling in innate cells and T cells, TAM inhibition could also jeopardize anticancer immune responses. This conflict is discussed in this review, describing the effects of TAM inhibition on cancer cells as well as immune cells, while also examining the intricate interplay of cancer and immune cells in the tumor microenvironment.

Original languageEnglish
Article number1195
JournalCancers
Volume13
Issue number6
Pages (from-to)1-16
Number of pages16
ISSN2072-6694
DOIs
Publication statusPublished - 10 Mar 2021

    Research areas

  • Axl, Cancer, MerTK, PD-1, Small molecule inhibitors, TAM receptors

ID: 65949955